Trial Profile
An Open-label, Multicenter Phase II Trial of Sunitinib for Patients With Chemo-refractory Metastatic Gastric Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jul 2011
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Barrett's oesophagus; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 13 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Jul 2008 Status changed from recruiting to in progress as reported by ClinicalTrials.gov.
- 04 Jan 2007 New trial record.